3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
58
Neoplasms
51
Lung Neoplasms
33
Colorectal Neoplasms
28
Carcinoma, Non-Small-Cell Lung
25
Prostatic Neoplasms
22
Melanoma
19
Pancreatic Neoplasms
17
Ovarian Neoplasms
16
Uterine Cervical Neoplasms
14
Sarcoma
12
Multiple Myeloma
12
Lymphoma
11
Glioma
11
Glioblastoma
11
Neoplasm Metastasis
10
Leukemia, Myeloid, Acute
10
Colonic Neoplasms
10
Neoplastic Cells, Circulating
9
Hematologic Neoplasms
9
Lymphoma, Follicular
8
Head and Neck Neoplasms
8
Carcinoma, Hepatocellular
8
Leukemia
7
Endometrial Neoplasms
7
Brain Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Papillomavirus Infections
6
Myelodysplastic Syndromes
6
Disease
6
Interventions
Temozolomide
11
Cyclophosphamide
11
Radiotherapy
7
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Cisplatin
6
Vincristine
5
Etoposide
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
sargramostim
3
Thiotepa
3
Melphalan
3
Carmustine
3
Automobiles
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
gallium Ga 68 dotatate
2
fludarabine
2
dactolisib
2
aldesleukin
2
Thalidomide
2
TH 302
2
Paclitaxel
2
Irinotecan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Everolimus
2
Donepezil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroectodermal Tumors, Primitive
×
Blood Specimen Collection
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled